Drug intelligence / Profile preview

sezanalumab

Development stage: Unknown
Lead developer: Roche
Modality: Small Molecules

Overview

Sezanalumab is a small molecule NLRP3 inflammasome inhibitor. It was initially developed by Inflazome, which was acquired by Roche in 2020. At the time of acquisition, sezanalumab was in preclinical to Phase 1 development. The drug is being investigated for its potential to treat NLRP3-driven inflammation, which is implicated in various diseases such as Parkinson's, Alzheimer's, and cardiovascular diseases. Roche's acquisition of Inflazome aimed to expand its presence in the neuroinflammation and chronic disease therapeutic areas.

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on sezanalumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sezanalumab.

Explore the full profile